

04-04-03

RECEIVED  
APR 09 2003  
FACH CENTER 160012900

Practitioner's Docket No. MNI-206 (MPI00-475P1RM)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Rory A.J. Curtis  
Application No.: 10/003,690 Group No.: 1652  
Filed: November 15, 2001 Examiner: MONSHIPOURI, MARYAM  
For: 55053, A NOVEL HUMAN EUKARYOTIC KINASE AND USES THEREFOR

Assistant Commissioner for Patents  
Washington, D.C. 20231

RESPONSE TO RESTRICTION REQUIREMENT TRANSMITTAL

1. Transmitted herewith for this application is/are:
  - a. This Transmittal (2 pages);
  - b. Response to Restriction Requirement (2 pages);
  - c. Transmittal of Information Disclosure Statement (2 pages – in duplicate);
  - d. Information Disclosure Statement (2 pages);
  - e. Form PTO/SB/08A (1 page);
  - f. Copies of References (BA-BB)
  - g. Revocation of Prior Powers of Attorney and Appointment of New Power of Attorney (2 pages)
  - h. Change of Attorney Docket Number (1 page)

STATUS

2. Applicant is other than a small entity.

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.  
37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10\*

- ☐ with sufficient postage as first class mail.

☒ as "Express Mail Post Office to Address"  
Mailing Label No. 292721925US

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.

Signature

Sean Hunziker/Carolyn Willey

(type or print name of person certifying)

Date: April 3, 2003

**\*WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Page 1 of 2)

Practitioner's Docket No. MNI-206 (MPI00-475P1RM)

**FEE DEFICIENCY**

3. If any extension and/or fee is required, charge Account No. 501668.  
If any fee for claims is required, charge Account No. 501668.

April 3, 2003

MILLENNIUM PHARMACEUTICALS, INC.

By 

Jean M. Silveri

Attorney Agent for Applicant


Registration No. 39,030

75 Sidney Street

Cambridge, MA 02139

Telephone - 617-679-7336

Facsimile - 617-551-8820



Practitioner's Docket No. MNI-206 (MPI00-475P1RM)

RECEIVED  
APR 09 2003  
PATENT  
TECH CENTER 1000/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Curtis, Rory A.J.  
Application No.: 10/003,690 Group No.: 1652  
Filed: November 15, 2001 Examiner: Maryam Monshipouri  
For: 55053, A NOVEL HUMAN EUKARYOTIC KINASE AND USES THEREFOR

Commissioner for Patents  
Washington, DC 20231

**RESPONSE TO RESTRICTION REQUIREMENT**

Dear Sir:

In response to the Restriction Requirement dated March 18, 2003, Applicants hereby elect Group I, drawn to isolated DNA molecules encoding a human Eukaryotic kinase, vectors, kits and host cells comprising said molecules and methods of expressing said molecules (claims 1-11 and 21).

Applicants hereby reserve the right to traverse the above restriction with respect to non-elected Groups II-VI in subsequent applications.

This paper is being filed timely, therefore Applicants believe that no extensions of time are required. In the event any extensions of time are necessary, the undersigned hereby authorizes the requisite fees to be charged to Deposit Account No. 501668.

**CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\***

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

- ☒ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.  
**37 C.F.R. SECTION 1.8(a)**

**37 C.F.R. SECTION 1.10\***

- ☐ with sufficient postage as first class mail. ☒ as "Express Mail Post Office to Address"  
Mailing Label No. EV292721925US

**TRANSMISSION**

- ☐ transmitted by facsimile to the Patent and Trademark Office.

Signature

Date: April 3, 2003

Sean Hunziker/Carolyn Willey  
(type or print name of person certifying)

**\*WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Entry of the remarks made herein is respectfully requested.

April 3, 2003

Respectfully submitted,

MILLENNIUM PHARMACEUTICALS, INC.

By 

Jean M. Silveri

Registration No. 39,030

75 Sidney Street

Cambridge, MA 02139

Telephone - 617-679-7336

Facsimile - 617-551-8820